Abstract The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was
Highlights • This study evaluated chronobiologic sleep parameters in major depressive disorder. • Nine depressed patients received open-label adjunctive brexpiprazole
Abstract Purpose/Background Evidence supports use of adjunctive atypical antipsychotics in major depressive disorder (MDD). Impaired sexual functioning is common in
Abstract Background: The treatment of patients with severe schizophrenia symptoms can be complicated and expensive. להמשך קריאה Nicole Meade et
Conclusions: Brexpiprazole has the potential to be an efficacious and well-tolerated treatment for agitation and hostility among patients with
Abstract Objective: To analyze the effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with major depressive disorder
Abstract Background: There is a need for effective, safe and well-tolerated pharmacotherapies for patients with major depressive disorder (MDD) who
Abstract Background Long-term treatment is recommended in major depressive disorder (MDD) to prevent relapse and to restore functioning. The aim
Abstract Objective Episodes of major depressive disorder (MDD) characterized by high levels of anxiety symptoms are less likely to respond
Abstract Background Hyperprolactinemia is an undesirable effect of most antipsychotics because of D2-receptor blockade. We assessed the effect of the
